Latest News

  • Cleveland Clinic Joins Mass General In Study To Diagnose Pediatric Pneumonia With Smartphone

    MobiHealthNews | ResApp, an Australian company developing an app to diagnose respiratory conditions based on cough sounds, has secured the first of three IRB approvals for its upcoming Smartcough-C pediatric trial, which will take place at the Cleveland Clinic, Massachusetts General Hospital, and a third site yet to be announced.

    Oct 24, 2016
  • What IBMs Genomic Partnership With Quest Says About Thermo Fisher Diagnostics Peers

    TheStreet | The collaboration between IBM and Quest "is certainly interesting for the clinical sequencing market," wrote Evercore ISI analyst Ross Muken in a Tuesday note, pointing to the goal of bringing next-generation sequencing (NGS) to community oncologists.

    Oct 19, 2016
  • Surprisingly Few New Parents Enlist in Study to Have Baby’s Genome Sequenced

    Science | When parents were offered option of having their newborn's genes probed to guide medical decisions via the BabySeq project, most declined. Only 7% of parents have agreed to participate.

    Oct 19, 2016
  • Gene Therapy In U.S. Is On Track For Approval Next Year

    MIT Technology Review | Spark Therapeutics is within striking distance of a landmark green light from the FDA for its treatment for certain forms of blindness.

    Oct 18, 2016
  • Illumina, Genentech, BIO Weigh in on FDA Draft Guidance on Companion Diagnostics

    RAPS | The draft guidance, released by FDA in July, is meant to be a practical guide to assist drug and in vitro diagnostic sponsors in developing the two products simultaneously.

    Oct 18, 2016
  • Episona Launches Male Infertility Test

    Diagnostics World Brief | Episona today announced the launch of its male fertility test, Seed. Seed evaluates epigenetic changes to DNA to predict the risk for male factor infertility and poor embryo development.

    Oct 17, 2016
  • White House To Announce Big Push For Cancer Blood Tests

    Forbes | The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.

    Oct 17, 2016
  • FDA Public Workshop Sheds Light On NGS Test Guidances

    Diagnostics World | On Friday, September 23, 2016, the FDA convened a public workshop on Adapting Regulatory Oversight of NGS-Based Tests, for discussion and comment on its recently released draft guidances for next generation sequencing based in-vitro diagnostic tests.

    Oct 13, 2016
  • Good Start Genetics Offers Two Disorder Test

    Diagnostics World Brief  Today, Good Start Genetics launched VeriYou, its saliva-based screening test for two of the most common inherited genetic disorders: cystic fibrosis (CF) and spinal muscular atrophy (SMA). The two-disorder test will be offered through physicians, and will serve as a complement to the multi-disorder testing the company offers.

    Oct 13, 2016
  • A Radical Revision of Human Genetics

    Nature News & Comment | Why many 'deadly' gene mutations are turning out to be harmless.

    Oct 12, 2016
  • JAX Plans Collaborations, New Lab in China

    Diagnostics World Brief | The Jackson Laboratory (JAX) and the Wenzhou Medical University and its affiliated hospitals (WMU) in China have announced a two-phase collaborative clinical genomics research agreement leveraging the research and scientific expertise of JAX and the clinical experience and expertise of WMU and its hospitals. The two groups will seek to better understand genomic propensities to disease and focus on individualized therapies for cancer, heart disease, and other afflictions.

    Oct 11, 2016
  • Q&A Confirming Next-Gen Sequencing Results with Sanger

    The Scientist | Ambry Genetics CEO Aaron Elliott discusses his team's recent analysis of 20,000 clinical next-generation sequencing panels.

    Oct 11, 2016
  • Hedge Fund Lawsuit Alleges Theranos Knowingly And Repeatedly Lied

    Forbes | Until now, there has been one big reason to believe that Theranos, the controversial diagnostics startup, could survive despite widespread doubts about whether its technology, which the company once promised would revolutionize the blood testing business, even works: its investors.

    Oct 11, 2016
  • Genetic Test Aims to Better Match Pancreatic Cancer Patients to Treatments

    MIT Technology Review | A nonprofit is tapping sequencing technology to guide treatment for thousands of patients.

    Oct 7, 2016
  • Baylor Genetics Looks to Improve Its IT with DRAGEN Processor

    Diagnostics World | Baylor Genetics has recently announced that it has chosen DRAGEN, the bio-IT Processor developed by Edico, as its main pipeline for analyzing samples and delivering data. The deployment is in direct correlation with Baylor Genetics’ Ready With Answers Initiative. 

    Oct 6, 2016
  • Theranos To Shut Labs, Lay Off Hundreds As Mission Shifts

    STAT | The embattled blood-testing company announced a major retrenchment, saying it will shut down its clinical labs and blood collection sites.

    Oct 6, 2016